Vera Therapeutics logo
VERAVera Therapeutics
Trade VERA now
Vera Therapeutics primary media

About Vera Therapeutics

Vera Therapeutics (NASDAQ:VERA) is a biotechnology company focused on advancing treatments for serious immunological diseases. Their operations are concentrated on developing and commercializing novel therapies aimed at improving the lives of patients battling conditions where current treatments fall short. A key project in their pipeline is the pursuit of innovative solutions for kidney diseases, with a strong emphasis on precision medicine to tailor treatments to individual patient needs. Vera Therapeutics is dedicated to pushing the boundaries of science to discover and develop therapies that can make a significant difference in patient care. Their objective is to lead with science-driven approaches, ensuring that their developments not only address unmet medical needs but also offer improved outcomes for patients worldwide.

What is VERA known for?

Snapshot

Public US
Ownership
2016
Year founded
61
Employees
California, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Products and/or services of Vera Therapeutics

  • Atacicept, a fusion protein aimed at treating IgA nephropathy by inhibiting APRIL and BLyS molecules implicated in B cell maturation.
  • MAU868, a monoclonal antibody for combating BK virus in kidney transplant patients.
  • Research in chronic autoimmune and inflammatory diseases, focusing on identifying novel treatments.
  • Collaborations with pharmaceutical companies to develop and commercialize innovative therapies.
  • Patient support programs designed to assist with access to treatments and managing chronic diseases.
  • Investment in advanced technologies for drug development and delivery systems.

Vera Therapeutics executive team

  • Dr. Marshall W. Fordyce M.D.Founder, President, CEO & Director
  • Dr. Robert M. Brenner M.D.Chief Medical Officer
  • Mr. Sean P. Grant M.B.A.Chief Financial Officer
  • Mr. David L. Johnson M.B.A.Chief Opearating Officer
  • Mr. Joseph R. Young M.B.A.Senior VP of Finance & Chief Accounting Officer
  • Dr. Allen Ebens B.Sc., Ph.D.Executive Vice President of Research
  • Ms. S. Sandra Park J.D.Senior VP of Legal, Healthcare,Commercial Law, Compliance & Operations
  • Ms. Debra CharlesworthVice President of Corporate Communications
  • Ms. Emma HaywoodVice President of Marketing
  • Ms. Julie PersonChief People Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.